Canada - Français
Updated ASCO Guidelines strongly recommend use of the Oncotype DX Breast Recurrence Score® Test in node-negative and the majority of node-positive early-stage breast cancer patients
TAILORx was independently led by ECOG-ACRIN Cancer Research Group with sponsorship from the National Cancer Institute. Participating cancer research groups included the Alliance for Clinical Trials in Oncology, NCIC-Clinical Trials Group, NRG Oncology, and SWOG.
The TAILORx trial followed over 10,000 women with early breast cancer for an average of 9 years. Over 1,000 trial sites in 6 countries participated.
NIH = National Institute of Health
RS = Recurrence Score result
TAILORx = A Clinical Trial Assigning IndividuaLized Options for Treatment (Rx)
The TAILORx trial was conducted independently by the ECOG-ACRIN Cancer Research Group.